Skip to main content
SpringerLink
Log in
Book cover

Female Urology pp 201–212Cite as

Intravesical Treatments for Overactive Bladder

  • Chapter

  • 1368 Accesses

Part of the book series: Current Clinical Urology ((CCU))

Abstract

Overactive bladder (OAB) is a recently defined symptom complex that includes urinary urgency with or without urge incontinence, urinary frequency (voiding eight or more times in a 24-h period), and nocturia (awakening two or more times at night to void) (1–3). The overall prevalence of OAB in Western Europe and the United States is 16–17% (4,5). The symptoms of OAB can affect quality of life and are associated with social, occupational, and psychological disruption.

This is a preview of subscription content, log in via an institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   169.00
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Hardcover Book
USD   219.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Abrams P, Wein AJ, eds. The Overactive Bladder: From Basic Science to Clinical Management Consensus Conference. Urology 1997;50(suppl):1–114.

    Google Scholar 

  2. Abrams P, Wein AJ, eds. Overactive Bladder and Its Treatments Consensus Conference. Urology 2000;55(suppl):1–84.

    Google Scholar 

  3. Staskin DR, Wein AJ, eds. New perspectives on the overactive bladder. Urology 2002;60(suppl): 1–104.

    Google Scholar 

  4. Milsom I, Abrams P, Cardozo L, Roberts RG, Thuroff J, Wein AJ. How widespread are the symptoms of an overactive bladder and how are they managed? A population-based prevalence study. BJU Int 2001;87:760.

    Article  CAS  PubMed  Google Scholar 

  5. Stewart W, Herzog AR, Wein A, et al. Prevalence and impact of overactive bladder in the US: results from the NOBLE program. Neurourol Urodyn 2001;20:406.

    Google Scholar 

  6. Lewis SA. Everything you wanted to know about the bladder epithelium but were afraid to ask. Am J Physiol Renal Fluid Electrolyte Physiol 2000;278:F867.

    CAS  PubMed  Google Scholar 

  7. Born M, Pahner I, Ahnert-Hilger G, Jons T. The maintenance of the permeability barrier of bladder facet cells requires a continuous fusion of discoid vesicles with the apical plasma membrane. Eur J Cell Biol 2003;82:343.

    Article  CAS  PubMed  Google Scholar 

  8. Andersson KE. Bladder activation: afferent mechanisms. Urology 2002;59(5 suppl 1):43.

    Article  PubMed  Google Scholar 

  9. Harris DR, Marsh KA, Birmingham AT, Hill SJ. Expression of muscarinic M3-receptors coupled to inositol phospholipid hydrolysis in human detrusor cultured smooth muscle cells. J Urol 1995;154:1241.

    Article  Google Scholar 

  10. Andersson KE. Drug therapy for urinary incontinence. Baillieres Best Pract Res Clin Obstet Gynaecol 2000;14:291.

    Article  CAS  PubMed  Google Scholar 

  11. Diokno AC, Lapides J. Oxybutynin: a new drug with analgesic and anticholinergic properties. J Urol 1972;108:307.

    CAS  PubMed  Google Scholar 

  12. Gajewski JB, Awad SA. Oxybutynin vs propantheline in patients with multiple sclerosis and detrusor hyperreflexia. J Urol 1986;135:966.

    CAS  PubMed  Google Scholar 

  13. Thuroff JW, Bunke B, Ebner A, et al. Randomized, double-blind, multicenter trial on treatment of frequency, urgency and incontinence related to detrusor hyperactivity: oxybutynin vs propantheline vs placebo. J Urol 1991;145:813.

    CAS  PubMed  Google Scholar 

  14. Gleason DM, Susset J, White C, Munoz DR, Sand PK. Evaluation of a new once-daily formulation of oxybutynin for the treatment of urinary urge incontinence. Urology 1999;54:420.

    Article  CAS  PubMed  Google Scholar 

  15. Anderson RU, Mobley D, Blank B, Saltzstein D, Susset J, Brown JS. Once daily controlled vs immediate release oxybutynin chloride for urge urinary incontinence. J Urol 1999;161:1809.

    Article  CAS  PubMed  Google Scholar 

  16. Birns J, Lukkari E, Malone-Lee JG. A randomized controlled trial comparing the efficacy of controlledrelease oxybutynin tablets (10 mg once daily) with conventional oxybutynin tablets (5 mg twice daily) in patients whose symptoms were stabilized on 5 mg twice daily of oxybutynin. BJU Int 2000;85:793.

    Article  CAS  PubMed  Google Scholar 

  17. Brendler CB, Radebaugh LC, Mohler JL. Topical oxybutynin chloride for relaxation of dysfunctional bladders. J Urol 1989;141:1350.

    CAS  PubMed  Google Scholar 

  18. Greenfield SP. and Fera M. The use of intravesical oxybutynin chloride in children with neurogenic bladder. J Urol 1991;146:532.

    CAS  PubMed  Google Scholar 

  19. Weese DL, Roskamp DA, Leach GE, Zimmern PE. Intravesical oxybutynin chloride: experience with 42 patients. Urology 1993;41:527.

    Article  CAS  PubMed  Google Scholar 

  20. deGroat WC, Kawatani M, Hisamitsu T, et al. Mechanisms underlying the recovery of urinary bladder function following spinal cord injury. J Auton Nerv Syst 1990;30:571.

    Google Scholar 

  21. Yoshimura N, Erdman SL, Snider NW, deGroat WC. Effects of spinal cord injury on neurofilament immunoreactivity and capsaicin sensitivity in rat dorsal root ganglion neurons innervating the urinary bladder. Neuroscience 1998;83:633.

    Article  CAS  PubMed  Google Scholar 

  22. Kawatani M, Whitney T, Booth AM, deGroat WC. Excitatory effect of substance P in parasympathetic ganglia of the cat urinary bladder. Am J Physiol 1989;257:R1450.

    CAS  PubMed  Google Scholar 

  23. Maggi CA, Santicioli P, Patacchini R, et al. Regional differences in the motor response to capsaicin in the guinea pig urinary bladder: relative role of preand postjunctional factors related to neuropeptide containing sensory nerves. Neuroscience 1988;27:675.

    Article  CAS  PubMed  Google Scholar 

  24. Maggi CA. Capsaicin and primary afferent neurons: from basic science to human therapy. J Auton Nerv Syst 1991;33:1.

    Article  CAS  PubMed  Google Scholar 

  25. Lembeck F. Capsicum and capsaicin: past, present and future. Acta Physiol Hung 1987;69:265.

    CAS  PubMed  Google Scholar 

  26. Dasgupta P, Fowler CJ. Chilies: from antiquity to urology. Br J Urol 1997;80:845.

    CAS  PubMed  Google Scholar 

  27. Montell C. Physiology, phylogeny, and functions of the TRP superfamily of cation channels. Science’s Stke: Signal Trans Knowl Environ 2001;(90):RE1.

    Google Scholar 

  28. Vennekens R, Voets T, Bindels RJ, Droogmans G, Nilius B. Current understanding of mammalian TRP homologues. Cell Calcium 2002;31:253.

    Article  CAS  PubMed  Google Scholar 

  29. Clapham DE. Some like it hot: spicing up ion channels. Nature 1997;389:783.

    Article  CAS  PubMed  Google Scholar 

  30. Jancso N. Role of the nerve terminals in the mechanism of inflammatory reactions, Bull Millard Fillmore Hosp 1960;7:53.

    Google Scholar 

  31. Jancso N, Jancso GA, Szolcsanyi J. The role of sensory nerve endings in neurogenic inflammation induced in human skin and in the eye and paw of the rat. Br J Pharmacol 1968;33:32.

    CAS  Google Scholar 

  32. Holzer, P. Capsaicin: cellular targets, mechanisms of action, and selectivity for thin sensory-neurons. Pharmacol Rev 1991;43:143.

    CAS  PubMed  Google Scholar 

  33. Scoville W. Note on capsicum. J Am Pharm Assoc 1912;1:453.

    CAS  Google Scholar 

  34. Kawatani M, Whitney T, Booth AM, deGroat WC. Excitatory effect of substance P in parasympathetic ganglia of the cat urinary bladder. Am J Physiol 1989;257:R1450.

    CAS  PubMed  Google Scholar 

  35. Szallasi A, Blumberg PM. Vanilloid receptors: new insights enhance potential as therapeutic target. Pain 1990;30:571.

    Google Scholar 

  36. Craft RM, Cohen SM, Porreca F. Long-lasting desensitization of bladder afferents following intravesical resiniferatoxin and capsaicin in the rat. Pain 1995;61:317.

    Article  CAS  PubMed  Google Scholar 

  37. Szolcsanyi J, Jancso-Gabor A, Joo F. Functional and fine structural characteristics of the sensory neuron blocking effect of capsaicin. Naunyn Schmiedebergs Arch Pharmacol 1975;287:157.

    Article  CAS  PubMed  Google Scholar 

  38. Buck SH, Burks TF. The neuropharmacology of capsaicin: review of some recent observations. Pharmacol Rev 1986;38:179.

    CAS  PubMed  Google Scholar 

  39. Ghatei MA, Gu J, Mulderry PK, et al. Calcitonin gene-related peptide (CGRP) in the female rat urogenital tract. Peptides 1985;6:809.

    Article  CAS  PubMed  Google Scholar 

  40. Maggi CA. Therapeutic potential of capsaicin-like molecules: studies in animals and humans. Life Sci 1992;51:1777.

    Article  CAS  PubMed  Google Scholar 

  41. Sharkey KA, Williams RG, Schultzberg M, Dockray GJ. Sensory substance P-innervation of the urinary bladder: possible site of action of capsaicin in causing urine retention in rats. Neuroscience 1983; 19:861.

    Article  Google Scholar 

  42. Jessell TM, Iversen LL, Cuello AC. Capsaicin-induced depletion of substance P from primary sensory neurons. Brain Res 1978;152:183.

    Article  CAS  PubMed  Google Scholar 

  43. Kashiba H, Ueda Y, Senba E. Systemic capsaicin in the adult rat differentially affects gene expression for neuropeptides and neurotrophin receptors in primary sensory neurons. Neuroscience 1997;76:299.

    Article  CAS  PubMed  Google Scholar 

  44. Maggi CA, Barbanti G, Samticioli P, et al. Cystometric evidence that capsaicin-sensitive nerves modulate the afferent branch of micturition reflex of humans. J Urol 1989;142:150.

    CAS  PubMed  Google Scholar 

  45. Lazzeri M, Beneforti P, Benaim G, Magi CA, Lecci A, Turini D. Intravesical capsaicin for treatment of severe bladder pain: a randomized placebo controlled study. J Urol 1996;156:947.

    Article  CAS  PubMed  Google Scholar 

  46. Flood H, Ireland L, Byrne DS, et al. Intravesical capsaicin for interstitial cystitis. J Urol 1997;157: 254A.

    Google Scholar 

  47. Fowler CJ, Jewkes D, McDonard WJ, Lynn B, deGroat WC. Intravesical capsaicin for neurogenic bladder dysfunction. Lancet 1992;339:1239.

    Article  CAS  PubMed  Google Scholar 

  48. Fowler CJ, Beck RO, Gerrard S, Betts CD, Fowler CG. Intravesical capsaicin for treatment of detrusor hyperreflexia. J Neurol Neurosurg Psychiatry 1994;57:169.

    Article  CAS  PubMed  Google Scholar 

  49. Geirsson G, Fall M, Sullivan L. Clinical and urodynamic effects of intravesical capsaicin treatment in patients with chronic traumatic spinal detrusor hyperreflexia. J Urol 1995;154:1825.

    Article  CAS  PubMed  Google Scholar 

  50. Das AS, Chancellor MB, Watanabe T, Sedor J, Rivas M. Intravesical capsaicin in neurogenic impaired patients with detrusor hyperreflexia. J Spinal Cord Med 1996;19:190.

    CAS  PubMed  Google Scholar 

  51. DeRidder DD, Chandramani V, Dasgupta P, vanPoppel H, Baert L, Fowler CJ. Intravesical capsaicin as a treatment for refractory detrusor hyperreflexia: a dual center study with long term follow-up. J Urol 1997;158:2087.

    Article  PubMed  Google Scholar 

  52. Wiart L, Joseph PA, Petit H, et al. The effects of capsaicin on the neurogenic hyperreflexic detrusor. A double blind placebo controlled study in patients with spinal cord disease. Preliminary results. Spinal Cord 1998;36:95.

    Article  CAS  Google Scholar 

  53. deSeze M, Wiart L, Joseph PA, Dosque JP, Mazaux JM, Barat M. Capsaicin and neurogenic detrusor hyperreflexia: a double-blind placebo-controlled study in 20 patients with spinal cord lesions. Neurourol Urodyn 1998;17:513.

    Article  PubMed  Google Scholar 

  54. Petersen T, Nielsen JB, Schroder HD. Intravesical capsaicin in patients with detrusor hyper-reflexia-a placebo-controlled cross-over study. Scand J Urol Nephrol 1999;33:104.

    Article  CAS  PubMed  Google Scholar 

  55. Caterina MJ, Schumacher MA, Tominaga M, Rosen TA, Levine JD, Julius D. The capsaicin receptor: a heat-activated ion channel in the pain pathway. Nature 1997;389:816.

    Article  CAS  PubMed  Google Scholar 

  56. Cruz F, Guaraes M, Silva C, Reis M. Suppression of bladder hyperreflexia by intravesical resinifera toxin. Lancet 1997;350:640.

    Article  CAS  PubMed  Google Scholar 

  57. Lazzeri M, Beneforti P, Turini D. Urodynamic effects of intravesical resiniferatoxin in humans: preliminary results in stable and unstable detrusor. J Urol 1997;158:2093.

    Article  CAS  PubMed  Google Scholar 

  58. Lazzeri M, Beneforti P, Turini D, Spinelli M, Zanollo A. Intravesical resiniferatoxin for the treatment of detrusor hyperreflexia refractory to capsaicin. J Urol 1998;159:83A.

    Article  Google Scholar 

  59. Lazzeri M, Beneforti P, Spinelli M, Zanollo A, Barbagli G, Turini D. Intravesical resiniferatoxin for the treatment of hypersensitive disorder: a randomized placebo controlled study. J Urol 2000; 164 (3 pt 1):676.

    Article  CAS  PubMed  Google Scholar 

  60. Payne CK, Mosbaugh PG, Forrest JB, et al. ICOS RTX Study Group (Resiniferatoxin Treatment for Interstitial Cystitis). Intravesical resiniferatoxin for the treatment of interstitial cystitis: a randomized, double-blind, placebo controlled trial. J Urol 2005;173:1590.

    Article  CAS  PubMed  Google Scholar 

  61. Watanabe T, Yokoyama T, Sasaki K, Nozaki K, Ozawa H, Kumon H. Intravesical resiniferatoxin for patients with neurogenic detrusor overactivity. Int J Urol 2004; 11:200.

    Article  CAS  PubMed  Google Scholar 

  62. Kim JH, Rivas DA, Shenot PJ, et al. Intravesical resiniferatoxin for refractory detrusor hyperreflexia: a multicenter, blinded, randomized, placebo-controlled trial. J Spinal Cord Med 2003;26:358.

    PubMed  Google Scholar 

  63. Kuo HC. Effectiveness of intravesical resiniferatoxin in treating detrusor hyper-reflexia and external sphincter dyssynergia in patients with chronic spinal cord lesions. BJU Int 2003;92:597.

    Article  CAS  PubMed  Google Scholar 

  64. Silva C, Rio ME, Cruz F. Desensitization of bladder sensory fibers by intravesical resiniferatoxin, a capsaicin analog: long-term results for the treatment of detrusor hyperreflexia. Eur Urol 2000;38:444.

    Article  CAS  PubMed  Google Scholar 

  65. deSeze M, Wiart L, deSeze MP, et al. Intravesical capsaicin vs resiniferatoxin for the treatment of detrusor hyperreflexia in spinal cord injured patients: a double-blind, randomized, controlled study. J Urol 2004;171:251.

    Article  PubMed  Google Scholar 

  66. Giannantoni A, Mearini E, DiStasi SM, et al. New therapeutic options for refractory neurogenic detrusor overactivity. Minerva Urol Nefrol 2004;56:79.

    CAS  PubMed  Google Scholar 

  67. Silva C, Ribeiro MJ, Cruz F. The effect of intravesical resiniferatoxin in patients with idiopathic detrusor instability suggests that involuntary detrusor contractions are triggered by C-fiber input. J Urol 2002;168:575.

    Article  CAS  PubMed  Google Scholar 

  68. Yokoyama T, Nozaki K, Fujita O, Nose H, Inoue M, Kumon H. Role of C afferent fibers and monitoring of intravesical resiniferatoxin therapy for patients with idiopathic detrusor overactivity. J Urol 2004;172:596.

    Article  PubMed  Google Scholar 

  69. Palma PC, Thiel M, Riccetto CL, Dambros M, Miyaoka R, Netto NR Jr. Resiniferatoxin for detrusor instability refractory to anticholinergics. Int Braz J Urol 2004;30:53.

    Article  PubMed  Google Scholar 

  70. Kuo HC. Multiple intravesical instillation of low-dose resiniferatoxin is effective in the treatment of detrusor overactivity refractory to anticholinergics. BJU Int 2005;95:1023.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Urology, Jefferson Medical College, Philadelphia, PA

    Craig B. Slotoroff MD & Dolores Shupp-Byrne PhD

  2. Department of Urology, Jefferson Medical College, Department of Urology, Philadelphia, PA

    Patrick J. Shenot MD

Authors
  1. Craig B. Slotoroff MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Dolores Shupp-Byrne PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Patrick J. Shenot MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Section of Female Urology and Voiding Dysfunction The Glickman Urological Institute, The Cleveland Clinic, Cleveland, Ohio

    Howard B. Goldman MD  & Sandip P. Vasavada MD  & 

  2. Department of Urology and Reproductive Biology, CASE School of Medicine, Cleveland, Ohio

    Howard B. Goldman MD

Rights and permissions

Reprints and permissions

Copyright information

© 2007 Humana Press Inc., Totowa, NJ

About this chapter

Cite this chapter

Slotoroff, C.B., Shupp-Byrne, D., Shenot, P.J. (2007). Intravesical Treatments for Overactive Bladder. In: Goldman, H.B., Vasavada, S.P. (eds) Female Urology. Current Clinical Urology. Humana Press. https://doi.org/10.1007/978-1-59745-368-4_13

Download citation

  • DOI: https://doi.org/10.1007/978-1-59745-368-4_13

  • Publisher Name: Humana Press

  • Print ISBN: 978-1-58829-701-3

  • Online ISBN: 978-1-59745-368-4

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation